Dicerna Pharma (DRNA) Misses Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress
November 7, 2019 4:05 PM ESTInitiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX2 Pivotal Clinical Trial
Announced Collaboration Agreement With Roche for Development of DCR-HBVS Including Option to Co-Fund Pivotal Development and Co-Promote in the U.S.
$312.7 Million in Cash, Cash Equivalents, and Marketable Securities at September 30, 2019; Dicerna to Receive $200.0 Million Upon Close of HBV Agreement with Roche
Management to Host Conference Call Today at 4:30 p.m. ET
CAMBRIDGE, Mass.--(BUSINESS... More
